welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
A Registered Cohort Study on Duchenne Muscular Dystrophy
study id #: NCT04012671
condition: Duchenne Muscular Dystrophy
Dystrophinopathy is a term of X-linked recessive genetic disease, including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and the X-linked dilated cardiomyopathy. The aim of this study is to determine the clinical spectrum and natural progression of dystrophinopathy in a prospective multicenter natural history study, to assess the clinical, genetic of patients with dystrophinopathy to optimize clinical management.
mechanism of action: No pharmaceutical intervention
last updated: February 25, 2020
start date: July 1, 2019
estimated completion: December 31, 2039
phase of development: N/A
size / enrollment: 2000
- Age at death [ Time Frame: 20 years ]
The time when patient die
• Eligible Sexes: all
• Beyond 2 years old
• Diagnosis with Duchenne Muscular Dystrophy, and female carriers, genotypically confirmed
• Diagnosis should be supported by muscle biopsy, if no genetic confirmation.
• Presence of other clinically significant illness
other Duchenne content
The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable MutationThis is an open label expanded access pr...
Hoda Abdel-Hamid, MDDr. Hoda Abdel Hamid is an Associate Pro...
Dame Kay Davies Explains Duchenne Muscular Dystrophy and Her Utrophin Researchhttps://player.vimeo.com/video/172905129...
Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular DystrophyWave Life Sciences Ltd. (Nasdaq: WVE), a...
Myosana Therapeutics, Inc. Raises Up To $1M from CureDuchenne VenturesMyosana Therapeutics, Inc., a new biotec...
Orthopedic and surgical management of the patient with Duchenne muscular dystrophyOrthopedic care is an important aspect o...
Peter Karachunski, MDDr. Karachunski is a University of Minne...